ANGPTL8 and metabolic dysfunction-associated steatotic liver disease: Circulating ANGPTL8 is increased in patients with T2D or non-alcoholic fatty liver diseases, which makes ANGPTL8 an attractive therapeutic target for metabolic syndromes22,36,37.